{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T09:21:38Z","timestamp":1795080098345,"version":"4.10.2"},"reference-count":37,"publisher":"The Journal of Rheumatology","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Rheumatol"],"published-print":{"date-parts":[[2016,7]]},"abstract":"<jats:sec><jats:title>Objective.<\/jats:title><jats:p>To determine the risk factors for permanent visual loss (PVL) in patients with biopsy-proven giant cell arteritis (GCA) and the usefulness of the factors in clinical practice.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods.<\/jats:title><jats:p>From 1976 through 2015, the clinical charts and laboratory results of 339 patients with biopsy-proven GCA were recorded prospectively at the time of diagnosis. We used multivariable logistic regression analysis to determine which of 24 pretreatment characteristics were associated with PVL.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results.<\/jats:title><jats:p>Visual ischemic manifestations occurred in 108 patients, including PVL in 53 (16%), bilaterally in 15 patients (28%). The independent predictors associated with an increased risk of PVL were age (OR 1.06, 95% CI 1.01\u20131.12, p = 0.01), a history of transient visual ischemic symptoms (OR 2.62, 95% CI 1.29\u20135.29, p &lt; 0.01), and jaw claudication (OR 2.11, 95% CI 1.09\u20134.10, p = 0.03). The presence of fever (OR 0.30, 95% CI 0.14\u20130.64, p &lt; 0.01) and rheumatic symptoms (OR 0.23, 95% CI 0.10\u20130.57, p = 0.001) were associated with a markedly reduced risk of developing visual loss (3.7% if features were both present). No laboratory variables were independently associated with PVL.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion.<\/jats:title><jats:p>The visual ischemic risk of untreated GCA can be readily estimated upon simple clinical findings, but not laboratory variables. However, we did not identify a subgroup of patients carrying no risk of developing visual loss. Glucocorticoid treatment remains, therefore, urgent for any patient with a high clinical suspicion index.<\/jats:p><\/jats:sec>","DOI":"10.3899\/jrheum.151135","type":"journal-article","created":{"date-parts":[[2016,5,2]],"date-time":"2016-05-02T00:12:56Z","timestamp":1462147976000},"page":"1393-1399","source":"Crossref","is-referenced-by-count":66,"title":["Risk Factors for Permanent Visual Loss in Biopsy-proven Giant Cell Arteritis: A Study of 339 Patients"],"prefix":"10.3899","volume":"43","author":[{"given":"Eric","family":"Liozon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Dalmay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrice","family":"Lalloue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume","family":"Gondran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holy","family":"Bezanahary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Laure","family":"Fauchais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim-Heang","family":"Ly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2262","published-online":{"date-parts":[[2016,5,1]]},"reference":[{"key":"2018112909361432000_43.7.1393.1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra011913"},{"key":"2018112909361432000_43.7.1393.2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.280.4.385"},{"key":"2018112909361432000_43.7.1393.3","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(199808)41:8<1497::AID-ART22>3.0.CO;2-Z"},{"key":"2018112909361432000_43.7.1393.4","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(01)00770-7"},{"issue":"Suppl 75","key":"2018112909361432000_43.7.1393.5","first-page":"S96","article-title":"Ocular involvement in giant cell arteritis","volume":"31","author":"Figus","year":"2013","journal-title":"Clin Exp Rheumatol"},{"key":"2018112909361432000_43.7.1393.6","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9394(99)80192-5"},{"key":"2018112909361432000_43.7.1393.7","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ken480"},{"key":"2018112909361432000_43.7.1393.8","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.140188"},{"key":"2018112909361432000_43.7.1393.9","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(199801)41:1<26::AID-ART4>3.0.CO;2-0"},{"key":"2018112909361432000_43.7.1393.10","doi-asserted-by":"publisher","DOI":"10.1097\/00005792-200009000-00001"},{"key":"2018112909361432000_43.7.1393.11","doi-asserted-by":"publisher","DOI":"10.1097\/01.md.0000119761.27564.c9"},{"key":"2018112909361432000_43.7.1393.12","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ken465"},{"key":"2018112909361432000_43.7.1393.13","doi-asserted-by":"publisher","DOI":"10.1002\/art.21075"},{"key":"2018112909361432000_43.7.1393.14","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(199910)42:10<2256::AID-ANR36>3.0.CO;2-Q"},{"key":"2018112909361432000_43.7.1393.15","doi-asserted-by":"publisher","DOI":"10.1097\/01.md.0000180042.42156.d1"},{"key":"2018112909361432000_43.7.1393.16","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1002\/art.1780330804","article-title":"Illustrated histopathologic classification criteria for selected vasculitis syndromes. American College of Rheumatology Subcommittee on Classification of Vasculitis","volume":"33","author":"Lie","year":"1990","journal-title":"Arthritis Rheum"},{"key":"2018112909361432000_43.7.1393.17","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780330810"},{"key":"2018112909361432000_43.7.1393.18","first-page":"1606","article-title":"Concurrent temporal (giant cell) arteritis and malignancy: report of 20 patients with review of the literature","volume":"33","author":"Liozon","year":"2006","journal-title":"J Rheumatol"},{"key":"2018112909361432000_43.7.1393.19","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(199804)41:4<701::AID-ART18>3.0.CO;2-P"},{"key":"2018112909361432000_43.7.1393.20","first-page":"207","article-title":"Dapsone in giant cell arteritis treatment","volume":"4","author":"Liozon","year":"1993","journal-title":"Eur J Intern Med"},{"key":"2018112909361432000_43.7.1393.21","doi-asserted-by":"publisher","DOI":"10.1016\/S0161-6420(93)31608-8"},{"key":"2018112909361432000_43.7.1393.22","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/36.2.251"},{"key":"2018112909361432000_43.7.1393.23","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.10.5.490"},{"key":"2018112909361432000_43.7.1393.24","first-page":"1272","article-title":"Silent, or masked, giant cell arteritis is associated with a strong inflammatory response and a benign short term course","volume":"30","author":"Liozon","year":"2003","journal-title":"J Rheumatol"},{"key":"2018112909361432000_43.7.1393.25","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-0579.2003.00223.x"},{"key":"2018112909361432000_43.7.1393.26","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.2006.113787"},{"key":"2018112909361432000_43.7.1393.27","first-page":"1548","article-title":"Influence of age, sex and place of residence on clinical expression of giant cell arteritis in northwest Spain","volume":"30","author":"Gonzalez-Gay","year":"2003","journal-title":"J Rheumatol"},{"key":"2018112909361432000_43.7.1393.28","first-page":"397","article-title":"No significant sex differences in temporal arteritis","volume":"31","author":"Liozon","year":"2004","journal-title":"J Rheumatol"},{"key":"2018112909361432000_43.7.1393.29","first-page":"1219","article-title":"Sex differences in giant cell arteritis","volume":"29","author":"Nir-Paz","year":"2002","journal-title":"J Rheumatol"},{"key":"2018112909361432000_43.7.1393.30","doi-asserted-by":"publisher","DOI":"10.1001\/jama.287.1.92"},{"key":"2018112909361432000_43.7.1393.31","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ken515"},{"key":"2018112909361432000_43.7.1393.32","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keu329"},{"key":"2018112909361432000_43.7.1393.33","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(199902)42:2<311::AID-ANR14>3.0.CO;2-F"},{"key":"2018112909361432000_43.7.1393.34","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0b013e318145275c"},{"key":"2018112909361432000_43.7.1393.35","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2015.06.009"},{"key":"2018112909361432000_43.7.1393.36","doi-asserted-by":"publisher","DOI":"10.1097\/01.md.0000145369.25558.b5"},{"key":"2018112909361432000_43.7.1393.37","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2007.10.014"}],"container-title":["The Journal of Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.3899\/jrheum.151135","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,11,29]],"date-time":"2018-11-29T19:09:39Z","timestamp":1543518579000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jrheum.org\/lookup\/doi\/10.3899\/jrheum.151135"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5,1]]},"references-count":37,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2016,7,1]]},"published-print":{"date-parts":[[2016,7]]}},"alternative-id":["10.3899\/jrheum.151135"],"URL":"https:\/\/doi.org\/10.3899\/jrheum.151135","relation":{},"ISSN":["0315-162X","1499-2752"],"issn-type":[{"value":"0315-162X","type":"print"},{"value":"1499-2752","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,5,1]]}}}